Advertisement

Lung Cancer

  • Kenneth F. Kessel
  • William T. Leslie

Abstract

Lung cancer is the most common cause of cancer death in men and women in the United States. In 1996 it was estimated there would be 177,000 new cases of lung cancer with 158,700 deaths (94,400 men, 64,300 women). The lifetime risk of dying from lung cancer in the United States is 1 in 12 for men and 1 in 19 for women.1 This number, however, is only a fraction of the tobacco-related deaths, which the World Health Organization estimates at 2.5 million annually worldwide, or one death every 13 seconds.2 In the United States there are estimated to be in excess of 400,000 smoking-related deaths each year.3

Keywords

Lung Cancer Small Cell Lung Cancer Nephrogenic Diabetes Insipidus Carcinogen Exposure Paraneoplastic Cerebellar Degeneration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Parker SL, Tong T, Bolden S, Wingo P. Cancer statistics 1996. CA Cancer J Clin 1996;46:5–27.PubMedCrossRefGoogle Scholar
  2. 2.
    Ile M, Kroll L. Tobacco advertising and the first amendment. JAMA 1990;264:1593–4.PubMedCrossRefGoogle Scholar
  3. 3.
    MMWR 1994;26:469–70.Google Scholar
  4. 4.
    Boyd JW, Himmelstein DU, Woolhandler S. The tobacco/ health insurance connection. Lancet 1995;346:64.PubMedCrossRefGoogle Scholar
  5. 5.
    Knudson AG. Genetics and etiology of human cancer. Adv Hum Genet 1977;8:1–66.PubMedGoogle Scholar
  6. 6.
    De Vita VT, Hellman S, Rosenberg SA. Cancer of the lung. In: Cancer: principles and practice of oncology Philadelphia: Lippincott, 1993:673–758.Google Scholar
  7. 7.
    Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029–35.CrossRefGoogle Scholar
  8. 8.
    Feld R, Ginsberg R, Payne D, Shepherd. Lung. In: Abeloff M, Armitage J, Lichter A, Niederhuber JE, editors. Clinical oncology. New York: Churchill Livingstone, 1995:1083–152.Google Scholar
  9. 9.
    Johanson GA. Physicians handbook of symptom relief in terminal care. 3rd ed. Home Hospice of Sonomon County, 1988.Google Scholar
  10. 10.
    Kubler-Ross E. On death and dying. New York: Macmillan, 1969.Google Scholar
  11. 11.
    Corn CA, Corr DM. Hospice care principles and practice. New York: Springer, 1983:1–363.Google Scholar
  12. 12.
    Carney DN. Lung cancer biology. Curr Opin Oncol 1991; 3:288.PubMedCrossRefGoogle Scholar
  13. 13.
    Coy P, Kennelly GM. The role of curative radiotherapy in the treatment of lung cancer. Cancer 1980;45:698–702.PubMedCrossRefGoogle Scholar
  14. 14.
    Yahalom J, Delaney TF, Oldfield E. Oncologic emergencies. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 4th ed. Philadelphia: Lippincott, 1993:2111–41.Google Scholar
  15. 15.
    Fischman A, Alpert N. FDG-PET in oncology: there’s more to it than looking at pictures. J Nucl Med 1993;34:6–11.PubMedGoogle Scholar
  16. 16.
    Beahrs OH, Henson D, Hutter R, Kennedy BJ. Handbook for staging cancer. Vol 19. Philadelphia: Lippincott, 1993:132–3.Google Scholar
  17. 17.
    Bonomi P, Faber LP, Recine D, Lincoln S. Carboplatin/etopos-ide/radiation plus escalating doses of paclitaxel in stage III non-small cell lung cancer: a preliminary report. Semin Oncol 1995;22:42–7.PubMedGoogle Scholar
  18. 18.
    Bonomi P, Reddy S, Faber LP. Concurrent chemotherapy and thoracic irradiation in non-small cell lung cancer. Hematol Oncol Clin North Am 1990;4:1143–58.PubMedGoogle Scholar
  19. 19.
    Gatzmeier U, Heckmayer M, Neuhauss R, et al. Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial. Semin Oncol 1995;22:24–8.Google Scholar
  20. 20.
    Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and car-boplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response and survival analysis. J Clin Oncol 1995;13:1860–70.PubMedGoogle Scholar
  21. 21.
    LeChevalier T, Pujol J, Douillard J, et al. A three arm trial of vinorelbine (navelbine) plus cisplatin, vindesine plus cis-platin and single agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis. Semin Oncol 1994;21:28–34.PubMedGoogle Scholar
  22. 22.
    Vinorelbine for treatment of advanced non-small cell lung cancer Med Lett 1995;37:72–3.Google Scholar
  23. 23.
    Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992; 327:1434–41.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Kenneth F. Kessel
  • William T. Leslie

There are no affiliations available

Personalised recommendations